Spectrum News NY1

Trump to tour police facilities in Nassau County on Friday

President Donald Trump will visit New York state on Friday to tour law enforcement facilities in Nassau County with Nassau County Executive and Republican candidate for governor Bruce Blakeman, a ...
dailyfreeman.com

High school girls volleyball: Mount Academy sweeps Our Lady of Lourdes

ESOPUS, N.Y. — Mount Academy’s volleyball team swept visiting Our Lady of Lourdes 25-14, 25-15, 25-23 to remain unbeaten in Mid-Hudson Athletic League (MHAL) volleyball action on Tuesday, Oct. 20. Top ...
myupnow

Copper Island Academy director attributes the charter school's growth the team's efforts

Copper Island Academy has partnered with Central Michigan University since 2021 to guide its development. The charter school program helps education leaders develop curricula aligned with state ...
BioSpace

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with ...
People

Teen, 16, Was Told She Had Cancer. Instead, Her Body Was Building a ‘Second Skeleton,’ Trapping Her in Bone (Exclusive)

Holly LaPrade now hopes to raise awareness for the rare genetic condition known as fibrodysplasia ossificans progressiva (FOP) Holly LaPrade At 16, Holly LaPrade was told she might have cancer before ...
WebMD

FDA Approves Atebrioz to Reduce Extra Bone Growth in Rare Gene Disorder

The FDA has approved Atebrioz (Zilurgisertib) for adults and children aged 12 or older who have fibrodysplasia ossificans progressiva (FOP). FOP is a very rare genetic disease that causes extra bone ...
contemporarypediatrics

FDA approves zilurgisertib for fibrodysplasia ossificans progressiva in patients aged 12 years and older

Zilurgisertib 100 mg orally once daily is now approved to reduce total new HO volume in patients with FOP aged 12 years and older, joining palovarotene and garetosmab as FDA-approved options. In ...
biopharmaapac

FDA Approves Mirum and Incyte’s Atebrioz for Fibrodysplasia Ossificans Progressiva

Atebrioz (zilurgisertib) receives US approval to reduce new heterotopic ossification in adults and paediatric patients aged 12 years and older with FOP. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and ...
streetinsider

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States ...
Morningstar%2c Inc.

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva -Once-daily oral ALK2 inhibitor ...
Healio

FDA approves Atebrioz tablets for fibrodysplasia ossificans progressiva

Please provide your email address to receive an email when new articles are posted on . The tablets have been approved for use in patients aged 12 years or older. This is the third approved treatment ...